HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yasuo Terauchi Selected Research

Glycemic Control

2/2024Efficacy of StepAdd, a Personalized mHealth Intervention Based on Social Cognitive Theory to Increase Physical Activity Among Patients With Type 2 Diabetes Mellitus: Protocol for a Randomized Controlled Trial.
11/2023Effects of hybrid closed-loop system on glycemic control and psychological aspects in persons with type 1 diabetes treated with sensor-augmented pump: A prospective single-center observational study.
6/2023Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
5/2023Sleep duration and food intake in people with type 2 diabetes mellitus and factors affecting confectionery intake.
1/2023Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
1/2023Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study.
1/2022The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
8/2021Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial.
1/2021A case of an elderly patient with insulin-dependent diabetes and dementia receiving one basal insulin plus one bolus insulin injections a day for 6 months.
4/2020The effect of long-term past glycemic control on executive function among patients with type 2 diabetes mellitus.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yasuo Terauchi Research Topics

Disease

140Type 2 Diabetes Mellitus (MODY)
04/2024 - 01/2002
71Insulin Resistance
01/2023 - 01/2002
43Body Weight (Weight, Body)
04/2024 - 07/2002
29Obesity
01/2023 - 01/2002
24Hypoglycemia (Reactive Hypoglycemia)
03/2024 - 04/2009
18Glucose Intolerance
10/2021 - 07/2002
15Inflammation (Inflammations)
01/2023 - 09/2002
14Non-alcoholic Fatty Liver Disease
01/2023 - 05/2007
13Hyperglycemia
11/2023 - 04/2003
12Diabetes Mellitus
12/2023 - 09/2006
11Fatty Liver
05/2024 - 05/2011
9Fibrosis (Cirrhosis)
04/2015 - 03/2005
8Albuminuria
04/2024 - 10/2007
8Hyperinsulinism (Hyperinsulinemia)
01/2023 - 06/2004
7Neoplasms (Cancer)
11/2023 - 06/2005
7Dyslipidemias (Dyslipidemia)
05/2023 - 06/2010
6Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 10/2012
6Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2017 - 10/2003
6Alcoholic Fatty Liver
02/2016 - 06/2010
6Hypertrophy
08/2008 - 01/2002
5Weight Loss (Weight Reduction)
06/2023 - 07/2014
5Liver Diseases (Liver Disease)
01/2023 - 01/2011
5Hypertension (High Blood Pressure)
04/2022 - 08/2005
5Type 1 Diabetes Mellitus (Autoimmune Diabetes)
06/2021 - 03/2017
5Carcinogenesis
02/2016 - 06/2005
5Atherosclerosis
10/2015 - 07/2002
4Drug-Related Side Effects and Adverse Reactions
01/2023 - 01/2016
4Heart Failure
01/2022 - 01/2016
4Atrophy
10/2020 - 01/2014
4Insulinoma
01/2017 - 03/2009
4Hyperplasia
01/2017 - 06/2004
4Hyperlipidemias (Hyperlipidemia)
01/2014 - 04/2005
3Diabetic Nephropathies (Diabetic Nephropathy)
04/2024 - 01/2019
3Hyperthyroidism
01/2023 - 01/2014
3Body Weight Changes
01/2022 - 01/2015

Drug/Important Bio-Agent (IBA)

76Glucose (Dextrose)FDA LinkGeneric
12/2023 - 01/2003
61Insulin (Novolin)FDA Link
05/2024 - 01/2002
32LipidsIBA
09/2020 - 01/2003
22Sitagliptin Phosphate (Januvia)FDA Link
12/2019 - 01/2010
21Blood Glucose (Blood Sugar)IBA
04/2024 - 04/2003
16Hypoglycemic Agents (Hypoglycemics)IBA
04/2023 - 12/2003
16AdiponectinIBA
09/2018 - 07/2002
15PPAR gammaIBA
12/2008 - 01/2002
14Triglycerides (Triacylglycerol)IBA
02/2019 - 02/2005
13Insulin Receptor Substrate ProteinsIBA
01/2020 - 11/2002
12SodiumIBA
12/2023 - 08/2005
12Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
12/2023 - 01/2016
10Insulin Glargine (Lantus)FDA Link
02/2024 - 03/2017
10LiraglutideFDA Link
06/2023 - 07/2012
10Hemoglobins (Hemoglobin)IBA
04/2022 - 01/2014
10LDL CholesterolIBA
02/2020 - 01/2007
9Sodium-Glucose Transporter 2 InhibitorsIBA
04/2024 - 03/2014
9LeptinIBA
01/2023 - 01/2003
9GlucokinaseIBA
10/2021 - 06/2004
8Glucagon-Like Peptide 1 (GLP 1)IBA
04/2023 - 01/2010
8ipragliflozinIBA
09/2020 - 01/2016
8miglitol (Glyset)FDA Link
02/2020 - 01/2010
7CreatinineIBA
04/2024 - 02/2015
7Metformin (Glucophage)FDA LinkGeneric
01/2023 - 05/2010
7lixisenatideIBA
12/2022 - 01/2016
7Insulin ReceptorIBA
10/2022 - 06/2003
7Dipeptidyl-Peptidase IV InhibitorsIBA
08/2022 - 04/2011
7oxidized low density lipoproteinIBA
02/2020 - 01/2007
6AlbuminsIBA
04/2024 - 01/2014
6Glucagon-Like Peptide-1 Receptor AgonistsIBA
04/2024 - 01/2019
6Fatty Acids (Saturated Fatty Acids)IBA
01/2023 - 01/2003
6CholesterolIBA
09/2020 - 09/2009
6Glucagon-Like Peptide-1 ReceptorIBA
11/2019 - 01/2014
6Pioglitazone (Actos)FDA Link
08/2017 - 09/2002
6Ezetimibe (Zetia)FDA Link
01/2014 - 09/2009
5semaglutideIBA
06/2023 - 01/2018
5EnzymesIBA
01/2023 - 06/2004
5glimepiride (Amarel)FDA LinkGeneric
01/2022 - 10/2011
5Biomarkers (Surrogate Marker)IBA
12/2021 - 05/2007
5CanagliflozinIBA
12/2021 - 03/2019
5HDL CholesterolIBA
12/2021 - 01/2007
56- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
11/2019 - 03/2014
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2019 - 01/2012
5Hormones (Hormone)IBA
01/2018 - 07/2002
5Glucagon (Glukagon)FDA Link
10/2017 - 11/2011
4SymportersIBA
12/2023 - 02/2016
4dulaglutideIBA
06/2023 - 01/2014
4Therapeutic UsesIBA
01/2023 - 05/2010
4anagliptinIBA
08/2022 - 01/2015
4alogliptinIBA
08/2022 - 06/2013
4empagliflozinIBA
01/2022 - 06/2014
43- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA
10/2020 - 06/2014
4IncretinsIBA
10/2017 - 11/2011
4LigandsIBA
04/2008 - 09/2002
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2003 - 09/2002
3Sodium-Glucose Transport ProteinsIBA
10/2023 - 04/2014
3C-Reactive ProteinIBA
11/2021 - 06/2006
3insulin degludecIBA
01/2021 - 03/2017
3Apolipoproteins E (ApoE)IBA
01/2021 - 01/2003
3IGF Type 1 Receptor (IGF 1 Receptor)IBA
10/2020 - 06/2014
3Glycoside Hydrolase InhibitorsIBA
02/2020 - 09/2009
3SteroidsIBA
06/2019 - 01/2014

Therapy/Procedure

41Glycemic Control
02/2024 - 08/2007
34Therapeutics
01/2023 - 08/2007
5Injections
04/2023 - 01/2009